by Jessica Casebolt | May 23, 2023 | Opioid/Substance Use Disorders, Tea Leaves
The Biden administration called on Congress Monday to pass a bill aimed at tackling fentanyl trafficking in the U.S., which would see the synthetic opioid raised to the highest classification of illegal drugs. The bill would permanently place all fentanyl-related...
by Jessica Casebolt | May 16, 2023 | M&A, Tea Leaves
The U.S. Federal Trade Commission is expected to file a lawsuit as early as Tuesday to block Amgen Inc’s $27.8 billion deal to buy Horizon Therapeutics PLC. Amgen struck a deal last year to buy Horizon to strengthen its rare diseases drugs portfolio. The company...
by Jessica Casebolt | May 16, 2023 | Life Sciences, Tea Leaves
CVS Health is closing down its clinical trials arm just two years after its launch. The company began its collaboration with pharmaceutical companies in 2021 and will shut it down at the end of 2024. To date,CVS Health has worked with more than 30 drugmakers on 50...
by Jessica Casebolt | May 16, 2023 | D.C. News, Tea Leaves
President Joe Biden on Monday nominated cancer specialist Dr. Monica Bertagnolli to become director of the National Institutes of Health (NIH). Bertagnolli is a cancer surgeon and researcher who, last fall became the first female head of the NIH’s National Cancer...
by Jessica Casebolt | May 16, 2023 | Access & Coverage, Tea Leaves
A federal appeals court Monday partially paused a ruling from a Texas district court judge that jeopardized access to free preventive care for 150 million Americans. The U.S. Court of Appeals for the 5th Circuit granted the Biden administration’s request for a partial...
by Jessica Casebolt | May 12, 2023 | D.C. News, Tea Leaves
A key Senate panel advanced a package of bipartisan bills aimed at improving generic drug competition and reforming the business practices of pharmacy benefit managers (PBMs). The bill would prohibit a PBM practice known as “spread pricing,” or charging health plans...
Recent Comments